36 results
Thumbnail

D1.103 - Two cases of discrepancy between fractional exhaled nitric oxide and airway eosinophils in asthma

Thumbnail

D1.104 - Severe Bronchial Asthma Phenotypes in a Referral Tertiary Center in Saudi Arabia

Thumbnail

D1.105 - Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy

Thumbnail

D1.106 - Grape polyphenols reduce the concentration of LPS in patients with asthma

Thumbnail

D1.107 - Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19

Thumbnail

D1.108 - Grape polyphenols increase the concentration of BPI in asthma patients who have had SARS-CoV-2

Thumbnail

D1.109 - Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy

Thumbnail

D1.110 - Analysis of clinical and anamnestic risk factors of bronchial asthma in children

Thumbnail

D1.111 - Improving severe asthma through psychological management of traumatic life events

Thumbnail

D1.112 - Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden

Thumbnail

D1.113 - Severe Asthma and Depression: the Overlooked Burden

Thumbnail

D1.114 - The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden

Thumbnail

D1.115 - Post-emergency asthma management

Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy

Thumbnail

D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients